Recent Company News

• 09:57 AM ET Mar 10, 2026
  

  Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026

• 08:09 AM ET Mar 02, 2026
  

  Results of Amarin's Icosapent Ethyl REDUCE-IT Post Hoc Analysis published in the European Journal of Preventive Cardiology ($13.80, 0.00)

• 08:42 AM ET Feb 25, 2026
  

  Transcript Intelligence: Amarin Corp. Q4 Earnings Guidance ($15.52, 0.00)

• 08:41 AM ET Feb 25, 2026
  

  Transcript Intelligence: Amarin Corp. Q4 Earnings Themes ($15.52, 0.00)

• 08:41 AM ET Feb 25, 2026
  

  Transcript Intelligence: Amarin Corp. Q4 Earnings Q&A ($15.52, 0.00)

• 07:02 AM ET Feb 25, 2026
  

  Amarin Corp. reports Q4 EPS $0.00 vs FactSet $0.03 [3 est, ($0.01)-0.11] ($15.52, 0.00)

• 03:28 PM ET Jan 16, 2026
  

  StreetAccount Summary - Politics of the Market preview: week of 19-Jan

• 02:46 PM ET Jan 16, 2026
  

  Supreme Court grants order to hear appeal of Hikma v Amarin (skinny label case) ($14.93, +0.03)

• 09:20 AM ET Jan 08, 2026
  

  StreetAccount Summary - US Pre-market trading update

• 08:21 AM ET Jan 08, 2026
  

  StreetAccount Summary - US Pre-market trading